Newron Pharmaceuticals S.p.A. | Ownership
Companies that own Newron Pharmaceuticals S.p.A.
Polar Capital LLP
398,525
2.23%
49,952
0.01%
07/31/2018
UBS AG (Investment Management)
321,949
1.8%
16,900
0%
09/04/2018
Zürcher Kantonalbank (Investment Management)
246,344
1.38%
-3,395
0.01%
07/31/2018
EFG Asset Management (UK) Ltd.
175,000
0.98%
0
0.28%
04/30/2018
Credit Suisse Asset Management (Schweiz) AG
143,236
0.8%
-1,880
0%
05/31/2018
Union Investment Privatfonds GmbH
120,000
0.67%
-29,140
0%
03/31/2018
Aviva Investors Global Services Ltd.
109,421
0.61%
0
0%
06/30/2018
Rhenus Capital AG
81,000
0.45%
-2,000
2.47%
07/27/2018
Herculis Partners SA
80,912
0.45%
-23,169
4.95%
07/31/2018
Rieter Fischer Partners AG
69,217
0.39%
0
0.25%
08/31/2018
| Address |
via Ludovico Ariosto 21
Bresso Milan 20091
Italy
|
|
Employees
|
- |
| Website |
http://www.newron.com |
| Updated |
07/08/2019 |
| Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Its products include Xadago for Parkinson's disease; sarizotan for patients with Rett syndrome; and ralfinamide for patients with rare pain indications. The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy. |
